PriceSensitive

Else Nutrition (TSXV:BABY) completes production trial run of its plant-based infant formula

Consumer
TSXV:BABY
13 October 2021 09:00 (EDT)
Else Nutrition - CEO, Hamutal Yitzhak.

Source: YouTube.

Else Nutrition (BABY) has successfully completed the first commercial trial run of its plant-based infant formula for age 0 -12 months.

The trial run leveraged a first-of-its-kind technological development with one of the raw ingredients in the plant-based formulation, resulting in a cleaner ingredient, while keeping the nutritional value fully intact.

Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition commented on the success of the trial run.

“This successful trial is a major step for the company, as we move forward to provide real choice when it comes to dairy-free infant formula. The $90 billion global infant formula market has been dominated by dairy and soy for too long. This development brings us one step closer to commercializing a minimally processed, plant-based option to millions of wanting families globally.” 

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults.

Else Nutrition Holdings Inc. (BABY) opened trading at C$2.47 per share.

Related News